The foreign drug manufacturer, Lupin Ltd., has decided to recall 9,210 bottles of the drug called Suprax. The recalled bottles of Suprax failed to pass various purity tests performed in the United States, according to the Food and Drug Administration. Although the defective products are alleged to be harmless by the manufacturer, purity tests are performed for the reason of identifying and removing potentially dangerous drugs from the market before anyone suffers injury. For this reason, New York consumers may wish to avoid consuming pills found in recalled bottles of Suprax -- for safety purposes.

Last year, Lupin Ltd. initiated a recall that affected even more bottles of its drugs when it recalled almost 65,000 bottles for discoloration problems. Other recalls affecting pharmaceuticals made by other manufacturers were also initiated this year. Sun Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., and Ranbaxy Laboratories have all been affected by recalls in this calendar year.

The recall of Suprax comes as the FDA applies more scrutiny to the purity and quality of pharmaceutical medications made in India, where Lupin Ltd. is located. At this time, four out of every 10 of the generic medicines and over-the-counter treatments sold to United States consumers were manufactured in India. Considering that these drugs are distributed to consumers across the country, it is commendable that the FDA is applying more scrutiny to Indian manufacturers.

Doctors administer Suprax to their patients in order to treat and prevent bacterial infections. Patients who are battling infections are highly susceptible to impurities that can be found in defective drugs, and it is important that drugs ingested by these patients -- including Suprax -- be subjected to the highest standards. Any New York resident who suspects that he or she has been hurt after taking dangerous drugs may wish to investigate the strength of pursuing a products liability claim under the law.

Source: Reuters, "Lupin pulls over 9,000 bottles of anti-infective Suprax from U.S. -FDA", April 15, 2014